Skin disease: In patients who do not respond to first-line therapies, followed by phototherapy and DMARDs, biologics are recommended. Biologics can also be used as first-line therapy without adjuncts in some patients.
Nail disease: Very few data exist for this subgroup, so drawing from skin psoriasis data, GRAPPA recommended biologics, particularly TNFi, for patients with moderate to severe nail involvement.
GRAPPA receives funding from pharmaceutical companies, which at present include AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly & Company, Novartis, Pfizer, and UCB, with Covagen and Crescendo as Innovation Partners. The authors reported that all deliberations and decisions were made completely independently of, and without input from or review by, any industry representatives.
On Twitter @whitneymcknight